In the phase III ETER701 study, the addition of benmelstobart (PD-L1 inhibitor) and anlotinib (VEGFR inhibitor) to EC chemotherapy markedly enhanced survival outcomes in treatment-naive ES-SCLC (25). The gene discussed is CD274; the disease is small cell lung carcinoma.